RPG Life Sciences Ltd. (RPGLIFE)
XNSE XNSE Primary MSE Summary
RPGLIFE Chart
People also search for
RPG Life Sciences Ltd. (RPGLIFE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has RPG Life Sciences Ltd. ever had a stock split?
RPG Life Sciences Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Ashok Nair CEO | XNSE Exchange | INE105J01010 ISIN |
| IN Country | 1,331 Employees | 9 Jul 2026 Last Dividend | - Last Split | - IPO Date |
Overview
RPG Life Sciences Limited represents a significant presence in the pharmaceutical sector with its comprehensive integration in the fields of developing, manufacturing, and marketing. The company showcases a broad spectrum of products ranging from branded formulations, generic medicines, to synthetic active pharmaceutical ingredients (APIs), catering to a wide international and Indian market. Initially known as RPG Pharmaceuticals Limited, the firm underwent a rebranding to RPG Life Sciences Limited in February 2008, illustrating a shift in its strategic direction or expansion in its product range. Founded in 1968 and with its headquarters in Mumbai, India, it operates under the umbrella of Nucleus Life Trust, indicating its status as a significant subsidiary in the healthcare and pharmaceutical domain.
Products and Services
- Synthetic Active Pharmaceutical Ingredients (APIs)
Offering a wide array of synthetic APIs in diverse therapeutic categories, including immunosuppressants for organ transplant management, anti-psychotic for mental health disorders, anti-anginal for heart conditions, anthelmintics for parasitic infections, anti-convulsant for seizure control, and anti-spasmodic for muscle spasms among others, catering to a broad spectrum of healthcare needs.
- Generics in Immunotherapy
Focused primarily on the realm of immunosuppressant therapy, RPG Life Sciences provides generic medications that are essential for patients undergoing organ transplants, ensuring accessibility to vital treatment options.
- Finished Dosage Formulations
The company extends its portfolio to include finished dosage formulations across a myriad of therapeutic areas. This range envisions delivering comprehensive healthcare solutions in nephrology for kidney health, rheumatology for autoimmune diseases, oncology for cancer treatments, gastroenterology for digestive disorders, cardiovascular for heart and blood systems, orthopedics for skeletal system conditions, respiratory for lung diseases, neurology for the nervous system, general health, urology for urinary diseases, anti-diabetic for diabetes management, anti-dengue as a treatment for dengue fever, alongside a selection of vitamins and minerals, gynecology for women’s health, pediatrics for children's medications, and more.
